NVO vs PFE
Novo Nordisk A/S and Pfizer, side by side.
Prices and company dataas of yesterday's close
- NVOSell some
Novo Nordisk still faces obesity share risk and weak analyst support, so we wouldn’t buy more and would sell some on a bounce.
- PFEBuy more21%
Pfizer's report on Nov 3 beat profit forecasts by 21%, and it pays a 5.8% dividend that it has raised for 15 years in a row.
Percent return
- NVO−12.23%
- PFE+23.18%
Nov 11, 2025 to Nov 11, 2026
Where they differ
- Company size: NVO $135B, PFE $143B.
- Sales growth, 1 yr: NVO +5.7%, PFE +1.3%. NVO is ahead.
- Price for $1 of next year's profit: NVO $12, PFE $10. PFE is ahead.
- Profit per $1 of sales: NVO 51¢, PFE 29¢. NVO is ahead.
- Cash minus debt: NVO −$88.1B, PFE −$49.1B. PFE is ahead.
- Price change, 1 yr: NVO −12%, PFE +23%. PFE is ahead. S&P 500 +12%.
- How much the price swings: NVO 36%, PFE 20%. PFE is ahead.
| Measure | NVONovo Nordisk A/S | PFEPfizer |
|---|---|---|
| Price and returns | ||
| Price | $41.10 | $29.44 |
| Today | Best in this row: +0.98% | +0.27% |
| 1 month | Best in this row: +6.34% | +5.66% |
| 3 months | −11.75% | Best in this row: +12.21% |
| This year | −15.21% | Best in this row: +26.19% |
| 1 year | −12.23% | Best in this row: +23.18% |
| 5 years | Best in this row: −18.74% | −23.09% |
| From 52-week high | −32.5% | −3.0% |
| How much it swings (90 days) | 36% | Best in this row: 20% |
| Valuation | ||
| Market value | $135B | $143B |
| Price vs last year's earnings | Best in this row: 10.2× | 19.2× |
| Price vs next year's expected earnings | 12.0× | Best in this row: 10.4× |
| Price to sales | 3.5× | Best in this row: 2.6× |
| Price vs cash it brings in | 16.6× | Best in this row: 14.2× |
| Company value vs operating profit | Best in this row: 6.9× | 8.7× |
| Price vs earnings, against its own past (0 = cheapest) | – | 20 |
| Growth | ||
| Revenue growth, 1 year | Best in this row: +5.7% | +1.3% |
| Revenue growth a year, last 3 years | Best in this row: +20.4% | −14.8% |
| Earnings per share growth, last year | Best in this row: +10.7% | −5.4% |
| Earnings per share growth expected next year | Best in this row: −1.4% | −3.0% |
| Profitability | ||
| Kept from sales after making the product | Best in this row: 83.3% | 74.9% |
| Kept as operating profit | Best in this row: 50.8% | 29.1% |
| Kept as final profit | Best in this row: 33.9% | 6.3% |
| Kept as spare cash | Best in this row: 21.5% | 18.5% |
| Profit on shareholders' money | Best in this row: 58.4% | 4.5% |
| Profit on all money put in | Best in this row: 42.6% | 12.8% |
| Balance sheet | ||
| Net cash (cash minus debt) | −$88.1B | Best in this row: −$49.1B |
| Debt for each $1 of shareholders' money | Best in this row: 0.62× | 0.71× |
| Short-term assets per $1 of bills due | 0.84× | Best in this row: 1.42× |
| Dividend yield | 3.18% | Best in this row: 5.85% |
| Share of profit paid as dividends | Best in this row: 34% | 245% |
| Our readPro | ||
| Our call | Sell some | Buy more |
| Why | Novo Nordisk still faces obesity share risk and weak analyst support, so we wouldn’t buy more and would sell some on a bounce. | Pfizer's report on Nov 3 beat profit forecasts by 21%, and it pays a 5.8% dividend that it has raised for 15 years in a row. |
| Where the price sits | in the full report | in the full report |
| Our overall score (out of 100) | Best in this row: 55 | 43 |
| Our value score | 78 | Best in this row: 87 |
| Our growth score | Best in this row: 42 | 2 |
| Our quality score | Best in this row: 83 | 59 |
| Our price trend score | 33 | Best in this row: 53 |
| Earnings and analysts | ||
| Analyst consensus | Hold | Hold |
| To average analyst target | Best in this row: +4.7% | +2.9% |
| Average analyst target | $43.04 | $30.28 |
| Analysts rating it a buy | 21% | Best in this row: 32% |
| Buy ratings added, 3 months | Best in this row: 0 | −1 |
| Analysts covering | 4 | 21 |
PFE: our only Buy more, with a better past year
Our pick of these: Pfizer
1-year return +23.2% vs −12.2%, S&P 500 +12.4%
NVO −12.2%, PFE +23.2%.Price trend score 53 of 100, vs 33
NVO 33, PFE 53.32% of analysts rate it a buy, vs 21%
NVO 21%, PFE 32%.Where it loses: NVO has faster sales growth, +5.7% vs +1.3%
Cover this stock to see the full report
The call, its reasons and what would change it are free for everyone. The price zones, the whole brief and how the call has moved come with covering a stock. Use one of your three covered slots, or go Pro for every stock.
Prices as of yesterday, 3:59 PM ET. A view, not advice.